Abstract
Protein denaturation processes involving aggregation are among the prime factors impeding the development of stable protein drug formulations. [...]
Highlights
Protein denaturation processes involving aggregation are among the prime factors impeding the development of stable protein drug formulations
A problem in designing rational strategies counteracting the aggregation is that a sound molecular basis underlying the denaturation process is usually not available
For our studies we used human growth hormone, which is a common therapeutic protein, and examined its aggregation mechanism under a range of process conditions. hGH is a single domain, globular protein consisting of 191 amino acids and has a molecular mass 22 kDa
Summary
Protein denaturation processes involving aggregation are among the prime factors impeding the development of stable protein drug formulations. Human Growth Hormone – Insights into its Aggregation Behavior using 1 Research Center Pharmaceutical Engineering GmbH, Graz, Austria 2 Institute of Biotechnology and Biochemical Engineering, University of Technology Graz, Graz, Austria
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
